172 related articles for article (PubMed ID: 9747629)
1. Advances in immunotherapy of hematologic malignancies.
Maloney DG
Curr Opin Hematol; 1998 Jul; 5(4):237-43. PubMed ID: 9747629
[TBL] [Abstract][Full Text] [Related]
2. Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches.
Maloney DG
Curr Opin Hematol; 1999 Jul; 6(4):222-8. PubMed ID: 10400370
[TBL] [Abstract][Full Text] [Related]
3. CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies.
Shanehbandi D; Majidi J; Kazemi T; Baradaran B; Aghebati-Maleki L
Curr Cancer Drug Targets; 2017; 17(5):423-444. PubMed ID: 28067179
[TBL] [Abstract][Full Text] [Related]
4. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.
Gupta IV; Jewell RC
Ann N Y Acad Sci; 2012 Aug; 1263():43-56. PubMed ID: 22830942
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based therapy of leukaemia.
Morris JC; Waldmann TA
Expert Rev Mol Med; 2009 Sep; 11():e29. PubMed ID: 19788782
[TBL] [Abstract][Full Text] [Related]
6. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
[TBL] [Abstract][Full Text] [Related]
7. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody therapy in haematological malignancies.
Chamuleau ME; van de Loosdrecht AA; Huijgens PC
Curr Clin Pharmacol; 2010 Aug; 5(3):148-59. PubMed ID: 20406175
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of reactive from neoplastic small-cell lymphoid aggregates in paraffin-embedded marrow particle preparations using L-26 (CD20) and UCHL-1 (CD45RO) monoclonal antibodies.
Bluth RF; Casey TT; McCurley TL
Am J Clin Pathol; 1993 Feb; 99(2):150-6. PubMed ID: 7679873
[TBL] [Abstract][Full Text] [Related]
10. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
[TBL] [Abstract][Full Text] [Related]
11. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
12. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Countouriotis A; Moore TB; Sakamoto KM
Stem Cells; 2002; 20(3):215-29. PubMed ID: 12004080
[TBL] [Abstract][Full Text] [Related]
13. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.
Nguyen DT; Amess JA; Doughty H; Hendry L; Diamond LW
Eur J Haematol; 1999 Feb; 62(2):76-82. PubMed ID: 10052709
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects.
Renner C; Trümper L; Pfreundschuh M
Leukemia; 1997 Apr; 11 Suppl 2():S55-9. PubMed ID: 9178842
[TBL] [Abstract][Full Text] [Related]
15. Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches.
Jurcic JG; Cathcart K; Pinilla-Ibarz J; Scheinberg DA
Curr Opin Hematol; 2000 Jul; 7(4):247-54. PubMed ID: 10882181
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
19. Novel antibodies against follicular non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Best Pract Res Clin Haematol; 2011 Jun; 24(2):231-56. PubMed ID: 21658621
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic monoclonal antibodies in onco-hematology].
Cartron G; Rossi JF
Med Sci (Paris); 2009 Dec; 25(12):1085-9. PubMed ID: 20035683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]